NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00078572,Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00078572,,COMPLETED,This study was designed to compare the efficacy and safety of an oral dual tyrosine kinase inhibitor in combination with capecitabine versus capecitabine alone in women with locally advanced or metastatic breast cancer that has not responded to previous therapy.,NO,Breast Cancer,DRUG: capecitabine|DRUG: lapatinib (GW572016),"Time to progression, randomization to time of progression or death due to breast cancer","Overall survival, from randomization until death due to any cause|progression-free survival, time from randomization until first documented sign of disease progression|6-month progression-free survival, six months after the date of randomization|overall tumor response rate (percentage of subjects achieving complete response (CR) or partial response (PR), response after randomization|clinical benefit rate (percentage of subjects with CR or PR or stable disease [SD] for â‰¥6 months), response after randomization|time to response, from randomization until first documented sign of CR/ PR|Quality of Life (QoL), duration of study|Safety, duration of study|Biomarkers, duration of study",,GlaxoSmithKline,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,408,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,100151,2004-03,2006-04,2010-02,2004-03-03,,2010-12-13,,
